(vianews) - the market ended the session with poxel (poxel.pa) rising 22.81% to €0.42 on thursday while cac 40 dropped 0.16% to €7,571.40.
poxel's last close was €0.34, 68.33% under its 52-week high of €1.08.
about poxel
poxel s.a., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. the company's lead product is twymeeg (imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in japan. it also develops pxl770, an adenosine monophosphate-activated protein kinase enzyme, which is in a phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (nash); pxl065, an earlier stage programs that is in phase 2 for the treatment of nash focusing on chronic and rare metabolic indications. the company has a licensing agreement with enyo pharma s.a.s. for the development of farnesoid x receptor that is in phase 2a study for the treatment of hepatitis b and nash; and deuterx llc for the development of pxl065, a mitochondrial pyruvate carrier inhibitor, which is in a phase i clinical trial for the treatment of nash. poxel s.a. was incorporated in 2009 and is headquartered in lyon, france.
earnings per share
as for profitability, poxel has a trailing twelve months eps of €-1.08.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, poxel's stock is considered to be oversold (<=20).
moving average
poxel's worth is way higher than its 50-day moving average of €0.36 and way under its 200-day moving average of €0.56.revenue growth
year-on-year quarterly revenue growth grew by 1050.6%, now sitting on 1.55m for the twelve trailing months.
more news about poxel (poxel.pa).